z-logo
Premium
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis
Author(s) -
Kagoya Yuki,
Seo Sachiko,
Nannya Yasuhito,
Kurokawa Mineo
Publication year - 2012
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2012.01628.x
Subject(s) - medicine , hyperlipidemia , calcineurin , gastroenterology , transplantation , hazard ratio , graft versus host disease , hypertriglyceridemia , etiology , multivariate analysis , cholesterol , diabetes mellitus , confidence interval , endocrinology , triglyceride
Hyperlipidemia is one of the late complications after allogeneic stem cell transplantation ( SCT ). Although intrahepatic cholestasis caused by chronic graft‐versus‐host disease ( GVHD ) or calcineurin inhibitors has been considered as possible etiologies, its prevalence, risk factors, and impact on prognosis have not been investigated well. We performed a retrospective analysis of 194 patients who underwent allogeneic SCT between 1995 and 2008 in our institute and survived more than 100 d after SCT . Overall, 83 (42.8%) and 99 (50.8%) patients developed hypercholesterolemia (≥240 mg/dL) and hypertriglyceridemia (≥200 mg/dL), respectively. In multivariate analysis, the development of chronic GVHD (hazard ratio [ HR ] 2.04, p < 0.05) and steroid use ( HR 2.24, p < 0.01) were independently associated with hypercholesterolemia, while administration of calcineurin inhibitors was not. As for the prognostic impact, multivariate analysis showed that the patients with hypercholesterolemia had a tendency of lower rate of relapse ( HR : 0.44, p = 0.07). There was no difference in non‐relapse mortality or overall survival between the groups. In conclusion, the development of hypercholesterolemia is regarded as one of the symptoms accompanied with chronic GVHD and might indicate a better control of the primary disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here